查詢結果分析
相關文獻
- Preliminary Results of Preoperative Chemoradiation Therapy for Cervical Esophageal Squamous Cell Carcinoma with Larynx Preservation
- The Cadaveric Study in the Hypopharyngeal Anatomy Framework to Assist in the Functional Laryngeal Surgery and Its Clinical Application
- Prognostic Factors Affecting the Outcome of Rectal Cancer Patients Receiving Preoperative Chemoradiotherapy Followed by Surgery
- Comparison between Pre-Operative Short Course Radiotherapy and Long Course Chemoradiotherapy in Patients with Locally Advanced Rectal Cancers
- The Improvements of Outcomes in Stage II-III, Middle and Lower Third Rectal Cancer Patients in Recently Ten Years: The Improvements Are Associated with Neo-adjuvant Concurrent Chemo-radiotherapy
頁籤選單縮合
題 名 | Preliminary Results of Preoperative Chemoradiation Therapy for Cervical Esophageal Squamous Cell Carcinoma with Larynx Preservation=頸部食道鱗狀細胞癌接受術前同步化學放射治療與喉部保留手術之初步結果 |
---|---|
作 者 | 戴坤耀; 黃文傑; 呂宜興; 蔡崇鑫; 詹梅麟; 林煥超; 蘇迺文; 陳裕仁; | 書刊名 | 放射治療與腫瘤學 |
卷 期 | 23:4 2016.12[民105.12] |
頁 次 | 頁237-247 |
分類號 | 416.36 |
關鍵詞 | 術前同步化學放射治療; 頸部食道鱗狀細胞癌; 喉部保留手術; Preoperative chemoradiotheraphy; Cervical esophageal cancer; Larynx preservation; |
語 文 | 英文(English) |
中文摘要 | 目的:術前同步化學放射治療合併手術已被廣泛運用於治療局部晚期非頸部食道癌。本研究目的在於針對頸部食道鱗狀細胞癌,評估術前同步化學放射治療合併喉部保留手術之可行性。材料與方法:本研究分析 11 名接受術前同步化學放射治療合併喉部保留手術之頸部食道鱗狀細胞癌患者。以同步整合加強照射技術給予 48 Gy 至腫瘤靶區,43.2 Gy 至潛在高風險區,同時給予 cisplatin 化學治療。藉由評估副作用,影像變化與病理反應來評估其初步療效。結果:共計 10 名病患完成術前同步化學放射治療,而有 1 名病患於同步化學放射治療中因為吸入性肺炎及敗血症導致死亡。完成術前同步化學放射治療的病患中,8 名接受食道腫瘤切除手術。手術後,4 名患者(50%)病理 T 分期改善,1 名患者(12.5%) 達到病理完全緩解。7 名患者(87.5%)保留喉部,且 6 名患者(75%)達到手術切口邊緣陰性。因化學放射治療導致的嚴重急性副作用,分別為分期 3 級咳嗽(1 名,10%)及分期 3 級貧血(1 名,10%)。根據外科醫師共識,能接受喉部保留手術的分界點為食道腫瘤距離喉部大於 2 公分。結論:頸部食道鱗狀細胞癌患者接受術前同步化學放射治療後進行喉部保留手術是可行的。未來是否能將多重模式治療運用於頸部食道鱗狀細胞癌病患以改善腫瘤控制率及生活品質,可將本研究的初步結果作為臨床驗證之參考。 |
英文摘要 | Purpose : Preoperative concurrent chemoradiotherapy (CCRT) followed by surgery has been widely accepted for treating locally advanced esophageal cancer except cervical esophageal cancer. This study aimed to evaluate the feasibility of preoperative CCRT followed by surgery for cervical esophageal squamous cell carcinoma (SCC) with intent to preserve the larynx. Materials & Methods : From August 2013 to August 2015, 11 patients with cervical esophageal SCC scheduled to receive preoperative CCRT with surgery were retrospectively analyzed. The gross tumor and involved lymphadenopathies were delivered with 48 Gy and 43.2 Gy to subclinical mucosal/submucosal disease and regional lymphatic basin in 24 fractions by simultaneously integrated boost (SIB) planning through intensity modulated radiation therapy (IMRT) or Tomotherapy. Chemotherapy with weekly cisplatin 30 mg/m^2 was administered during radiation therapy (RT) course. Side effects grading was according to the Common Terminology Criteria for Adverse Events (CTCAE version 4.0). The image assessment and pathological responses were recorded and graded. Results : Among all 11 patients, ten of them had received the planned CCRT completely and one was dead due to aspiration pneumonia and sepsis during CCRT course. Of the 10 patients who completed preoperative CCRT, 8 patients of them have received esophagectomy. The pathological T down-staging was noted in 4 patients (50%) and pathological complete response (pCR) was achieved in 1 patient (12.5%). Seven of these 8 patients (87.5%) preserved the larynx and 6 patients (75%) achieved negative surgical margins (R0 resection). The most severe acute toxicities from CCRT were grade 3 cough (n=1, 10%) and grade 3 anemia (n=1, 10%). According to chest surgeons’ consensus, the cut-off point for larynx-preserving surgery after CCRT for cervical esophageal cancer could be 2-cm distance from esophageal tumor to larynx. Conclusion : Preoperative CCRT followed by larynx-sparing surgery is feasible in cervical esophageal SCC. The preliminary results can be used as a reference for further clinical validation of multimodality therapy in cervical esophageal SCC with intent to improve tumor control and quality of life. |
本系統中英文摘要資訊取自各篇刊載內容。